

Miren Altuna-Azkargorta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2255265/publications.pdf>

Version: 2024-02-01

33
papers

550
citations

949033

11
h-index

843174

20
g-index

36
all docs

36
docs citations

36
times ranked

601
citing authors

#	ARTICLE	IF	CITATIONS
1	The A β ¹⁻⁴² /A β ¹⁻⁴⁰ ratio in CSF is more strongly associated to tau markers and clinical progression than A β ¹⁻⁴² alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	3.0	18
2	Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 838412.	1.4	1
3	Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review. <i>Medicina (Lithuania)</i> , 2022, 58, 473.	0.8	6
4	Progressive cognitive impairment and familial spastic paraparesis due to PRESENILIN 1 mutation: anatomoclinical characterization. <i>Journal of Neurology</i> , 2022, , 1.	1.8	1
5	Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4307.	1.8	14
6	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2212910.	2.8	47
7	DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients. <i>Biomedicines</i> , 2022, 10, 1380.	1.4	2
8	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
9	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 119.	3.0	6
10	Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity. <i>Journal of Clinical Medicine</i> , 2021, 10, 2776.	1.0	43
11	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
12	Sleep Disorders in Adults with Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3012.	1.0	12
13	Association of Apolipoprotein E ϵ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	4.5	32
14	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	2.8	7
15	Late-onset epileptic seizures in adults with Down syndrome are linked to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
16	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021, 10, 50.	3.6	32
17	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
18	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
19	Neuropsychological correlates of plasma NfL in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
20	Alzheimer's disease clinical onset and age at death in people with Down syndrome: A systematic review and population-based study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
21	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
22	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12052.	1.2	7
23	Evaluation of biochemical and hematological parameters in adults with Down syndrome. <i>Scientific Reports</i> , 2020, 10, 13755.	1.6	4
24	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	4.4	21
25	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e041255.	0.4	0
26	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. <i>Alzheimer's and Dementia</i> , 2020, 16, e041500.	0.4	0
27	The effect of APOE ϵ 4 in Alzheimer's disease biomarkers in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e042889.	0.4	0
28	1 H-MRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e043346.	0.4	0
29	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. <i>Alzheimer's and Dementia</i> , 2020, 16, e043491.	0.4	0
30	Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12047.	1.2	25
31	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , 2020, 395, 1988-1997.	6.3	164
32	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	1.8	44
33	O2019: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P558.	0.4	0